ClinicalTrials.gg
Not yet recruitingNCT07310836Updated Dec 30, 2025

A Retrospective Study of Safety and Efficacy of Locoregional Therapies Combined With Anti-VEGF/TKIs and Immune Checkpoint Inhibitors for All Comers of Intention-to-treat Patients With Hepatocellular Carcinoma Beyond UCSF Criteria Before Liver Transplantation

An observational study in Hepatocellular Carcinoma and Liver Transplantation, sponsored by Ningbo Medical Center Lihuili Hospital. Not yet recruiting. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2025-12-30.

Sponsored by Ningbo Medical Center Lihuili Hospital · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Retrospective
Enrollment
300
Ages
16 Years and older
Sex
All
01

Study summary

This is a single-center, retrospective cohort study aiming to evaluate the safety and efficacy of a combined treatment strategy for patients with hepatocellular carcinoma (HCC) who are beyond the UCSF criteria but intended for liver transplantation. The primary objective is to assess the outcomes of these "intention-to-treat" patients who received locoregional therapies (LRT, such as TACE or radiotherapy) in combination with systemic therapy (anti-VEGF/Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors) as a "conversion therapy" prior to potential transplantation. This approach is distinct from traditional bridging or down-staging therapies by incorporating more aggressive systemic regimens. The study plans to enroll 300 subjects. The exposure group will include approximately 100 patients beyond UCSF criteria who received the combined conversion therapy between January 2020 and December 2024. A control group of about 200 patients who met the UCSF criteria and were directly listed for transplantation in the same period will be used for comparison. Data will be collected from medical records and the China Liver Transplant Registry (CLTR), with follow-up until December 2025.

Primary outcome measures include:

Objective Response Rate (ORR) of conversion therapy per mRECIST. Rate of successful down-staging to meet UCSF criteria.

1-, 2-, and 3-year overall survival (OS) rates of the intention-to-treat population.

Actual liver transplantation rate after successful conversion. Post-transplant 1-, 2-, and 3-year OS and recurrence-free survival (RFS) rates.

Secondary outcomes involve:

Safety profiles of both conversion therapy and subsequent transplantation. Analysis of factors influencing conversion success and treatment efficacy. Determination of an optimal washout period for Immune Checkpoint Inhibitors prior to transplantation.

The study seeks to provide high-level evidence for optimizing pre-transplant conversion strategies for advanced HCC patients currently outside standard transplant criteria.

02

Conditions studied

  • Hepatocellular Carcinoma
  • Liver Transplantation
03

In context

Carcinoma, Hepatocellular

3,656 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,068 are open to participants now.

This study's planned enrollment of 300 is above the median of 200 across 853 observational studies indexed under Carcinoma, Hepatocellular.

Browse Carcinoma, Hepatocellular studies →

Lead sponsor

Ningbo Medical Center Lihuili Hospital is the lead sponsor of 16 studies on the registry; 13 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

This retrospective, single-center cohort study plans to include 300 patients with HCC. All patients were managed at the study center between January 1, 2020, and December 31, 2024.

  1. Beyond UCSF Criteria Cohort (n = 100): Patients with HCC tumors exceeding the UCSF transplant criteria but intended for liver transplantation. All patients in this cohort received multimodal conversion therapy, combining locoregional therapies with systemic therapy.
  2. Within UCSF Criteria Cohort (n = 200): A control group of patients whose HCC tumors met the UCSF criteria at the time of listing and were directly registered for liver transplantation without receiving the aforementioned conversion therapy.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥16;
  • Clinical diagnosis of HCC;
  • CNLC Stage I-IIIA.

Exclusion criteria

Exclusion Criteria:

  • Extrahepatic ;
  • Type IV portal vein tumor thrombus.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Observational model
Case-control
Time perspective
Retrospective
Enrollment
300 participants (estimated)
Patient registry
No

Groups and cohorts

  • Beyond UCSF Criteria Cohort

    HCC patients receiving conversion therapy beyond UCSF criteria

    Combination Product: Locoregional Therapy (LRT) + Systemic Drug Therapy

  • Within UCSF Criteria Cohort

    HCC patients within UCSF Criteria Cohort

Interventions

  • Combination productLocoregional Therapy (LRT) + Systemic Drug Therapy

    Treatment regimens, doses, and durations varied based on individual clinical decisions and are collected retrospectively.

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR)

    Proportion of patients achieving a Complete Response (CR) or Partial Response (PR) according to mRECIST criteria during the conversion therapy period.

    Time frame: From the start of conversion therapy until the completion of therapy (assessed up to 24 months).

  2. Successful Down-staging Rate to UCSF Criteria

    Proportion of patients whose tumor burden is reduced to meet the UCSF transplant criteria after conversion therapy, based on imaging and tumor marker assessment.

    Time frame: From the start of conversion therapy until the date of meeting UCSF criteria or therapy termination (assessed up to 24 months).

  3. 1/2/3-year Overall Survival (OS) Rate

    The proportion of patients who received conversion therapy and are still alive at 1, 2, and 3 years after the transplantation surgery, analyzed using the Kaplan-Meier method.

    Time frame: From the initiation of conversion therapy, assessed at 1, 2, and 3 years.

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided — A specific plan for sharing de-identified individual participant data (IPD) from this retrospective study is under development. The final decision will depend on several factors, including but not limited to: institutional review board (IRB) approval, compliance with data privacy regulations, and the establishment of appropriate data use agreements. If shared, the data would likely include demographic, clinical treatment, tumor response, and survival outcome data to support validation of study findings. The research team is committed to evaluating the possibility of sharing data in a manner that protects participant confidentiality and contributes to scientific knowledge.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Dec 2025; primary completion for Dec 2025, 0 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 16, 2025
First posted
Dec 30, 2025
StartEst.
Dec 20, 2025
Primary completionEst.
Dec 31, 2025
CompletionEst.
Mar 31, 2026
Last update
Dec 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07310836
Lead sponsor
Ningbo Medical Center Lihuili Hospital
Responsible party
lucaide (Chief Physician/Professor, Ningbo Medical Center Lihuili Hospital) — Principal investigator
First posted
Dec 30, 2025
Start date
Dec 20, 2025 (estimated)
Primary completion
Dec 31, 2025 (estimated)
Completion
Mar 31, 2026 (estimated)
Last update
Dec 30, 2025

Study contacts

Caide Lu, Professor
Contact
lucaide@nbu.edu.cn
+8613957800900
Shuqi Mao, Professor
Contact
mmmaoshuqi@163.com
+8617855848257
Caide Lu, Professor
principal investigator · Ningbo Medical Centre Lihuili Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion